Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q1 2026 · 10-Q
Revenue$200.40M$200.40M+2.3% vs Q1 2025 Net Income-$34.10M-$34.10MN/M vs Q1 2025 EPS Diluted-$0.36-$0.36— vs Q1 2025 Gross Profit$137,600,000+2.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Operating Cash Flow-$15,700,000N/M Margins · derivedGross margin68.7%+0.2 pt vs Q1 2025
Operating margin-15.3%−0.5 pt vs Q1 2025
Net margin-17.0%−17.0 pt vs Q1 2025
ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end